10.6084/m9.figshare.5558575.v1
Sohda M.
Sohda
M.
Miyazaki T.
Miyazaki
T.
Honjyo H.
Honjyo
H.
Hara K.
Hara
K.
Ozawa D.
Ozawa
D.
Sakai M.
Sakai
M.
Yokobori T.
Yokobori
T.
Higuchi T.
Higuchi
T.
Tsushima Y.
Tsushima
Y.
Kuwano H.
Kuwano
H.
Supplementary Material for: 18F-FAMT PET Is Useful to Distinguish between Specific Uptake and Nonspecific Uptake Compared to 18F-Flourodeoxyglucose Position Emission Tomography in Esophageal Cancer Patients
Karger Publishers
2017
18F-FAMT PET
18F-flourodeoxyglucose position emission tomography
Specific uptake
Nonspecific uptake
Esophageal cancer
2017-11-01 10:03:24
Journal contribution
https://karger.figshare.com/articles/journal_contribution/Supplementary_Material_for_18F-FAMT_PET_Is_Useful_to_Distinguish_between_Specific_Uptake_and_Nonspecific_Uptake_Compared_to_18F-Flourodeoxyglucose_Position_Emission_Tomography_in_Esophageal_Cancer_Patients/5558575
<p><b><i>Background:</i></b> L-[3-<sup>18</sup>F]-α-methyltyrosine (<sup>18</sup>F-FAMT)
solely accumulates in tumor cells via an amino acid transport system.
This selective uptake pattern results in a very high tumor-to-background
ratio, enabling clear delineation of the tumor. The purpose of the
present study was to assess the significance of <sup>18</sup>F-FAMT PET, which shows little nonspecific uptake compared to <sup>18</sup>F-flourodeoxyglucose position emission tomography (FDG PET) in esophageal cancer patients. <b><i>Methodology:</i></b> PET-CT studies with <sup>18</sup>F-FAMT and <sup>18</sup>F-FDG
were performed as part of pretreatment work-up in 82 patients with
histologically confirmed esophageal cancer. We evaluated nonspecific
uptakes of <sup>18</sup>F-FDG and <sup>18</sup>F-FAMT PET. <b><i>Results:</i></b> The nonspecific uptake of <sup>18</sup>F-FAMT PET was lower than that of <sup>18</sup>F-FDG PET (<i>p = </i>0.282). In the operation group, 26.1% demonstrated nonspecific uptake in <sup>18</sup>F-FDG PET, whereas only 2.38% (1 case) demonstrated nonspecific uptake in <sup>18</sup>F-FAMT PET (<i>p = </i>0.433). In the inoperable group, 47.5% showed nonspecific uptake in <sup>18</sup>F-FDG PET, whereas 5.0% showed nonspecific uptake in <sup>18</sup>F-FAMT PET (<i>p = </i>0.079). <b><i>Conclusion:</i></b> A crucial point for the diagnostic value of PET is distinguishing specific and nonspecific uptake. <sup>18</sup>F-FAMT-PET is a very superior modality with regard to the lower rate of nonspecific uptake in esophageal cancer.</p>